Processa Pharmaceuticals (PCSA) CEO buys 2,136 shares in open market
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,136 shares of common stock at $2.535 per share. After this transaction, he directly holds 2,136 shares. He also reports indirect ownership of 800 shares through the Ng Cha Family Trust and 3,488 shares through an account labeled George Ng IRRA FOB George Ng.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,136 shares ($5,415)
Net Buy
3 txns
Insider
Ng George K
Role
Chief Executive Officer
Bought
2,136 shs ($5K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 2,136 | $2.535 | $5K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,136 shares (Direct, null);
Common Stock — 3,488 shares (Indirect, George Ng IRRA FOB George Ng)
Footnotes (1)
Key Figures
Shares purchased: 2,136 shares
Purchase price: $2.535 per share
Direct holdings after transaction: 2,136 shares
+3 more
6 metrics
Shares purchased
2,136 shares
Open-market purchase of common stock
Purchase price
$2.535 per share
Price paid for 2,136 common shares
Direct holdings after transaction
2,136 shares
Common stock held directly by George K. Ng
Indirect holdings via Ng Cha Family Trust
800 shares
Common stock held indirectly
Indirect holdings via IRRA account
3,488 shares
Common stock held indirectly in George Ng IRRA FOB George Ng
Net buy shares
2,136 shares
Net buy direction in transaction summary
Key Terms
open-market purchase, indirect ownership, Form 4/A, transaction summary
4 terms
open-market purchase financial
"Purchase in open market or private transaction"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
indirect ownership financial
"direct_or_indirect: "I", nature_of_ownership: "Ng Cha Family Trust""
Form 4/A regulatory
"INSIDER FILING DATA (Form 4/A)"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
transaction summary financial
""transactionSummary": { "buyCount": 1, "sellCount": 0"
FAQ
What insider transaction did PCSA CEO George Ng report on this Form 4/A?
George K. Ng reported buying 2,136 shares of Processa Pharmaceuticals common stock in an open-market purchase at $2.535 per share. This filing also updates his direct and indirect holdings as of March 31, 2026, showing his current ownership positions.
Does the PCSA Form 4/A show any insider stock sales by George Ng?
No insider stock sales are reported for George K. Ng in this Form 4/A. The filing shows one open-market purchase of 2,136 shares and two holding-only entries for existing indirect positions, indicating a net-buy direction for the period covered.
What is the overall buy versus sell activity for George Ng in this PCSA filing?
The transaction summary shows one buy transaction totaling 2,136 shares and no sales. Two additional entries simply record indirect holdings. Overall, the Form 4/A reflects a net-buy position for George K. Ng during the reported period for Processa Pharmaceuticals.